Lineage Cell Therapeutics Inc (LCTX) — Cash Flow-to-Debt Ratio
Lineage Cell Therapeutics Inc (LCTX) has a Cash Flow-to-Debt Ratio of -0.05x as of September 2025, meaning its operating cash flow of $-3.62 Million could theoretically repay 0% of its total liabilities ($68.84 Million) in one year. Explore LCTX long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Lineage Cell Therapeutics Inc Cash Flow-to-Debt Ratio (1991–2024)
Historical debt coverage capacity for Lineage Cell Therapeutics Inc across 34 annual periods. Also explore Lineage Cell Therapeutics Inc (LCTX) total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Lineage Cell Therapeutics Inc (1991–2024)
Year-by-year debt coverage analysis for Lineage Cell Therapeutics Inc. For market capitalisation and broader financial context, see Lineage Cell Therapeutics Inc market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.64x | $-23.09 Million | $36.21 Million | ▲ +12.9% |
| 2023 | -0.73x | $-28.57 Million | $39.00 Million | ▼ -3678.2% |
| 2022 | 0.02x | $1.06 Million | $51.73 Million | ▲ +107.3% |
| 2021 | -0.28x | $-23.56 Million | $83.65 Million | ▲ +81.7% |
| 2020 | -1.54x | $-19.75 Million | $12.82 Million | ▲ +31.4% |
| 2019 | -2.24x | $-31.95 Million | $14.23 Million | ▲ +31.6% |
| 2018 | -3.28x | $-30.88 Million | $9.41 Million | ▲ +3.5% |
| 2017 | -3.40x | $-30.52 Million | $8.98 Million | ▲ +3.1% |
| 2016 | -3.51x | $-42.33 Million | $12.06 Million | ▼ -43.5% |
| 2015 | -2.45x | $-44.54 Million | $18.21 Million | ▲ +23.3% |
| 2014 | -3.19x | $-38.85 Million | $12.18 Million | ▼ -67.2% |
| 2013 | -1.91x | $-29.51 Million | $15.47 Million | ▲ +47.1% |
| 2012 | -3.61x | $-19.68 Million | $5.45 Million | ▼ -16.0% |
| 2011 | -3.11x | $-13.59 Million | $4.37 Million | ▼ -54.7% |
| 2010 | -2.01x | $-7.73 Million | $3.85 Million | ▼ -12.6% |
| 2009 | -1.79x | $-4.26 Million | $2.39 Million | ▼ -499.0% |
| 2008 | -0.30x | $-1.60 Million | $5.38 Million | ▲ +22.6% |
| 2007 | -0.38x | $-1.24 Million | $3.22 Million | ▲ +23.3% |
| 2006 | -0.50x | $-1.26 Million | $2.52 Million | ▲ +23.5% |
| 2005 | -0.66x | $-1.41 Million | $2.16 Million | ▲ +49.8% |
| 2004 | -1.31x | $-1.54 Million | $1.18 Million | ▼ -599.1% |
| 2003 | -0.19x | $-654.14K | $3.50 Million | ▲ +76.6% |
| 2002 | -0.80x | $-2.13 Million | $2.67 Million | ▲ +49.3% |
| 2001 | -1.57x | $-3.21 Million | $2.04 Million | ▲ +88.3% |
| 2000 | -13.50x | $-4.86 Million | $359.75K | ▼ -82.9% |
| 1999 | -7.38x | $-4.39 Million | $595.51K | ▼ -40.6% |
| 1998 | -5.25x | $-2.10 Million | $400.00K | ▼ -626.9% |
| 1997 | -0.72x | $-1.30 Million | $1.80 Million | ▲ +93.1% |
| 1996 | -10.50x | $-2.10 Million | $200.00K | ▲ +0.0% |
| 1995 | -10.50x | $-2.10 Million | $200.00K | ▼ -110.0% |
| 1994 | -5.00x | $-2.00 Million | $400.00K | ▲ +68.8% |
| 1993 | -16.00x | $-1.60 Million | $100.00K | ▼ -23.1% |
| 1992 | -13.00x | $-1.30 Million | $100.00K | ▼ -333.3% |
| 1991 | -3.00x | $-600.00K | $200.00K | — |